Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus.

Intervirology - 1 Jan 2004

Hosaka Tetsuya, Suzuki Fumitaka, Suzuki Yoshiyuki, Saitoh Satoshi, Kobayashi Masahiro, Someya Takashi, Sezaki Hitomi, Akuta Norio, Tsubota Akihito, Arase Yasuji, Ikeda Kenji, Kumada Hiromitsu

Abstract excerpt

OBJECTIVE: Adefovir dipivoxil (ADV) is a nucleoside analogue that inhibits wild-type hepatitis B virus (HBV) and lamivudine-resistant HBV mutants in vitro and in vivo. The aim of this study was to evaluate the efficacy of ADV against lamivudine-resistant mutants and of adefovir and interferon (IF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Alanine Transaminase
Share to Drug Resistance, Microbial

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B

Share to Interferon-alpha

Share to Lamivudine

Share to Organophosphonates

Share to Safety

Source

Identifiers

PMID: 15564749
DOI: 10.1159/000080881

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-15564749-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus.PMID 15564749Read ↗

Efficacy of adefovir dipivoxil in the treatment of lamivudine-resistant hepatitis B virus genotype C infection.Semantic proximity Read ↗

Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant chronic hepatitis B.Semantic proximity Read ↗

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.Semantic proximity Read ↗

Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.Semantic proximity Read ↗

[The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].Semantic proximity Read ↗

Treatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B.Semantic proximity Read ↗

[Antiviral efficacy of lamivudine/adefovir combination therapy in chronic hepatitis b patients with resistance to lamivudine and adefovir consecutively].Semantic proximity Read ↗

[Efficacy of the 96-week adefovir dipivoxil therapy in patients with chronic hepatitis B].Semantic proximity Read ↗

Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil.Semantic proximity Read ↗

Screening and identification of a novel adefovir dipivoxil resistance associated mutation, rtN236V, of HBV from a large cohort of HBV-infected patients.Semantic proximity Read ↗

Resistant mutants induced by adefovir dipivoxil in hepatitis B virus isolates.Semantic proximity Read ↗

Delayed Reduction of Hepatitis B Viral Load and Dynamics of Adefovir-Resistant Variants during Adefovir plus Entecavir Combination Rescue Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.